A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation

Rudy E. Fuentes,1 Sergei Zaitsev,2,3 Hyun Sook Ahn,1 Vincent Hayes,1 M. Anna Kowalska,1 Michele P. Lambert,4 Yuhuan Wang,1 Donald L. Siegel,5 Daniel W. Bougie,6 Richard H. Aster,6 Daniel D. Myers,7 Victoria Stepanova,5 Douglas B. Cines,5 Vladimir R. Muzykantov,2,3 and Mortimer Poncz1,4

1Division of Hematology, The Children’s Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, USA. 2Institute for Translational Medicine and Therapeutics, 3Department of Pediatrics, and 4Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 5Blood Research Institute, Blood Center of Wisconsin, Milwaukee, Wisconsin, USA. 6Department of Surgery, University of Michigan Health Systems, Ann Arbor, Michigan, USA.


The use of fibrinolytic agents to prevent new thrombus formation is limited by an increased risk of bleeding due to lysis of hemostatic clots that prevent hemorrhage in damaged blood vessels. We sought to develop an agent that provides thromboprophylaxis without carrying a significant risk of causing systemic fibrinolysis or disrupting hemostatic clots. We previously showed that platelet (PLT) α granule–delivered urokinase plasminogen activator (uPA) is highly effective in preventing thrombosis, while being associated with little systemic fibrinolysis or bleeding. Here, we generated a chimeric prodrug composed of a single-chain version of the variable region of an anti-αIIbβ3 mAb fused to a thrombin-activatable, low-molecular-weight pro-uPA (PLT/uPA-T). PLT/uPA-T recognizes human αIIbβ3 on both quiescent and activated platelets and is enzymatically activated specifically by thrombin. We found that this prodrug binds tightly to human platelets even after gel filtration, has a prolonged half-life in mice transgenic for human αIIb compared with that of uPA-T, and prevents clot formation in a microfluidic system. Importantly, in two murine injury models, PLT/uPA-T did not lyse preexisting clots, even when administration was delayed by as little as 10 minutes, while it concurrently prevented the development of nascent thrombi. Thus, PLT/uPA-T represents the prototype of a platelet-targeted thromboprophylactic agent that selectively targets nascent over preexisting thrombi.

Introduction

There is a substantial and important unmet need to prevent thrombus formation without lysing preexisting hemostatic clots, especially in settings in which the risks of both thrombosis and bleeding are high. (1) This situation occurs commonly, for example, after major general or orthopedic surgery, in which the risk of thrombosis in the absence of effective intervention may exceed 50%, and mortality from symptomatic pulmonary embolism approaches 10% (2). Yet, the risk of perioperative bleeding often delays the introduction of anticoagulation by several days. Similar tradeoffs in the timing of anticoagulation based on the risk of bleeding arise in patients with ischemic stroke and those who have sustained traumatic brain injury or extensive general trauma. In these and related settings, there is a clear need for therapies that distinguish between preexisting hemostatic clots and nascent, potentially occlusive thrombi.

Fibrinolytic agents such as tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) are highly effective at lysing thrombi, but have short half-lives in the circulation, cause systemic fibrinolysis, and predispose patients to bleeding, because they permeate preexisting hemostatic clots (3). Moreover, both PAs have vasoactive and neurotoxic side effects (4, 5) due to signaling through identified cell-surface receptors (5) and diffusion through the blood-brain barrier after stroke. Therefore, the clinical application of fibrinolytic agents has been limited primarily to the management of a small subset of patients with acute ischemic stroke or acute life- or limb-threatening thromboembolism (6, 7).

One potential way to rectify the short in vivo lifespan, nonselective permeation of hemostatic and vaso-occlusive clots, deleterious interaction with cellular receptors, and permeation into neurologic and other tissues is to harness the drug to cells that reside within the blood. We have used this approach successfully by linking PAs to rbc and shown that this approach provides enduring and safe thromboprophylaxis in several animal models (8). However, rbc are not rapidly and selectively recruited to sites of incipient thrombus formation, unlike platelets, which provide procoagulant surfaces in a temporally and regionally restricted manner. This raises the possibility that targeting PAs to the surface of platelets would enhance their delivery and invert the function of platelets from prothrombotic to fibrinolytic and do so in a manner that would not lyse mature clots that are no longer recruiting platelets.

In support of this possibility, it is known that Quebec platelet disorder (QPD), a mild-to-moderate inherited platelet disorder, is caused by the ectopic expression and storage of uPA in platelet α granules (9). Bleeding in these patients is typically restricted...
to surgical stress and is responsive to inhibitors of PAs such as tranexamic acid (TEA) (10). A transgenic mouse expressing uPA in the α granules of circulating platelets has a phenotype similar to that of QPD patients (11). These QPD mice do not bleed spontaneously or develop systemic fibrinolysis, but they are capable of preventing the formation of occlusive thrombi in a FeCl$_3$ carotid injury model and a pulmonary microembolism model (11). Importantly, it is only necessary to infuse uPA-expressing platelets into WT mice to a level of approximately 5% of total platelets to completely prevent occlusive thrombi in the FeCl$_3$ injury model without causing noticeable bleeding (11). These studies suggest that the release of activated PAs within growing thrombi is especially effective in preventing further expansion and may help explain why over 90% of the PA inhibitor 1 (PAI-1) available in the circulation is stored in platelet α granules (12).

To test this hypothesis and to translate it into a clinically viable thromboprophylactic agent, we generated a construct that has an N-terminal single-chain variable fragment (scFv) of a mAb directed against human αIIb (CD41a), which is part of the most abundant receptor on the platelet surface (13), fused to a low-molecular-weight (LMW) pro-uPA (thrombin-activatable, LMW pro-uPA [PLT/uPA-T]) into which a thrombin-specific cleavage and activation site was introduced at its N-terminus (Figure 1A). Here, we characterize platelet targeting of this prodrug and demonstrate its thrombolytic efficacy both in vitro and in vivo. We established what we believe to be two novel dual-injury murine models that show that PLT/uPA-T selectively prevents the generation of occlusive nascent thrombi, relatively sparing even recently formed clots from lysis (Figure 1B). The clinical implications of these findings are discussed herein.

**Results**

**Generation and in vitro characterization of PLT/uPA-T.** Our goal was to develop a thrombin-activatable thrombolytic prodrug that would target the surface of human platelets without perturbing their function. The targeted platelets would then serve as natural carriers to localize the prodrug in nascent thrombi, which are actively incorporating platelets and where the prodrug could be activated by thrombin (Figure 1B). We modeled our platelet-targeting construct on a previously described rbc-targeting scFv/uPA-T (8). In PLT/uPA-T, the rbc scFv is replaced with a PLT scFv derived from an anti-human αIIb mAb at its N-terminus (Figure 1, C and D). We selected the αIIbβ3 receptor as the platelet-specific vascular target in part because of its abundance on the platelet surface, which would allow for a wide dosing range depending on the indication (13). A series of anti-human αIIb-specific mAbs were tested. The mAb 312.8 was selected on the basis of its high affinity for human platelets, lack of binding to WT mouse platelets, binding to hαIIbβ3 mouse platelets (data not shown and Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI81470DS1), and lack of interference with platelet aggregation (Supplemental Figure 1B).

PLT/uPA-T contained the same LMW uPAzymogen (uPA-T) on its C-terminus as the rbc fusion protein and consisted of a deletion of two amino acids that lead to loss of a plasmin cleavage site and creation of a thrombin activation site that must be proteolyzed before fibrinolytic activity is expressed in vitro (Figure 2A). uPA-T and PLT/uPA-T are inactivated by the lysine analog TEA, which blocks binding of plasminogen to fibrin (14). Kinetics studies showed that the rate of activation of PLT/uPA-T by thrombin was almost 2 times slower than that of uPA-T (Supplemental Figure 2A), though thrombin cleavage of both appeared sensitive to the presence of antithrombin (Supplemental Figure 2B). Using a series of serine proteases, the proteolytic activation of PLT/uPA-T was found to be restricted to thrombin (Figure 2B).

Binding of PLT/uPA-T to nonactivated and phorbol myristate acetate-activated (PMA-activated) human platelets was identical as assessed by flow cytometry (Figure 3A). In contrast, PLT/uPA-T did not bind to quiescent or activated WT murine platelets but did bind to both states of hαIIbβ3 murine platelets, which express human αIIb complexed to mouse β3 (15) (Figure 3A). PLT/uPA-T bound immobilized human αIIbβ3 with a $K_D$ of approximately 5 nM (Figure 3B). PLT/uPA-T did not interfere with aggregation of human platelets by adenosine diphosphate (ADP) (Figure 3C).

**Microfluidic thrombosis studies using gel-filtered platelets.** To test platelet delivery of PLT/uPA-T and to begin to determine fibrinolytic efficacy, isolated human platelets were incubated with various concentrations of PLT/uPA-T or uPA-T prodrug and then gel filtered (Figure 4A). The filtered platelets were then added back to blood to reconstitute “whole blood,” and clotting was activated by either adding factor VIIia (FVIIia) (16) or by producing a heparin-induced thrombocytopenia-like (HIT-like) prothrombotic state by adding PF4 and the HIT-like mAb KKO (17). The samples were then flowed into a microfluidic channel (Figure 4A). PLT/uPA-T, but not uPA-T, was detected on the platelet surface after gel filtration (Figure 3A). Compared with uPA-T at a comparable starting dose, PLT/uPA-T significantly decreased thrombus development, as indicated by a reduction in both fibrin and platelet accumulation after addition of FVIIia (Figure 4, B and C, respectively) or after induction of an HIT-like state (Supplemental Figure 3, A and B). Similar studies were performed using baboon platelets, which also bound PLT/uPA-T (Supplemental Figure 4A). Again, PLT/uPA-T blocked thrombus growth, as indicated by decreased fibrin and platelet accumulation in the microfluidic system relative to uPA-T (Supplemental Figure 4, B and C, respectively). These data are consistent with our finding that PLT/uPA-T bound to the platelet surface remains present after gel filtration, while uPA-T does not bind to the platelet surface and is lost with filtration.

**Thrombolytic prodrug half-life and systemic effects in mice.** Labeled uPA-T and PLT/uPA-T were infused into WT and hαIIbβ3 mice, and binding to the platelet surface was monitored. PLT/uPA-T bound to hαIIbβ3 with a half-life of approximately 2 hours, and bound drug was still detectable at 24 hours (Figure 5, A and B). In contrast, PLT/uPA-T did not bind to WT platelets at any concentration tested (data not shown), and uPA-T did not bind to any source of platelets (Figure 5A and data not shown for WT mice studies). Intravenous infusion of PLT/uPA-T or uPA-T did not cause a significant fall in platelet numbers compared with that seen in the PBS control (Figure 5C). A bolus of either uPA-T or PLT/uPA-T followed by infusion did not cause a rise in D-dimers or a significant fall in fibrinogen levels (Figure 5D).

**Models of nascent versus preexisting thrombi: FeCl$_3$, carotid arterial versus tail-clipping injuries.** The primary goal in developing PLT/uPA-T was to be able to selectively lyse nascent pathological
Figure 1. Schematics of the construction and biology of PLT/uPA-T. (A) Schematic construct of the scFv N-terminal and LMW uPA-T C-terminal portions of PLT/uPA-T. Right: C-terminal zymogen of human single-chain uPA (scuPA) lacking the full molecule domains and modified by deleting Phe157 and Lys158 (in red), which convert a plasmin activation site into the thrombin-activatable uPA-T. tcuPA, two-chain urokinase; P, proline; R, arginine; F, phenylalanine; K, lysine; I, isoleucine; s-s, cysteine disulfide bonds. (B) Intended biology of a chimeric PLT/uPA-T that would bind to the surface of resting or activated platelets without activating these cells and be attracted to a nascent thrombus, whereby available thrombin would activate the urokinase moiety uPA-T, leading to plasminogen activation and subsequent fibrinolysis. Preexisting clots, which do not bind new platelets except transiently within the shell and have little or no active thrombin, or at least no accessible thrombin, are protected from lysis by PLT/uPA-T. tcuPA, two-chain urokinase; P, proline; R, arginine; F, phenylalanine; K, lysine; I, isoleucine; s-s, cysteine disulfide bonds. (B) Intended biology of a chimeric PLT/uPA-T that would bind to the surface of resting or activated platelets without activating these cells and be attracted to a nascent thrombus, whereby available thrombin would activate the urokinase moiety uPA-T, leading to plasminogen activation and subsequent fibrinolysis. Preexisting clots, which do not bind new platelets except transiently within the shell and have little or no active thrombin, or at least no accessible thrombin, are protected from lysis by PLT/uPA-T.
thrombi without affecting preexisting clots that might be required for hemostasis. Several thrombosis models were used to determine whether PLT/uPA-T was capable of demonstrating those abilities. In the first model, hdblB^mice were studied to examine the ability of the prodrug to prevent nascent thrombus formation after a FeCl₃-sclerosing carotid arterial injury, while sparing loss of hemostatic stability in preexisting tail-clip injuries (Figure 6, A and B). Prodrug dosing was based on the studies in Figure 4 and Supplemental Figure 3 and 4. Prodrugs were injected as a bolus, followed by continuous infusion of the same dose over the ensuing 30 minutes (bolus infusion). We chose this approach because a bolus of 5 mg/kg uPA-T — in contrast to a bolus of 0.5 mg/kg PLT/uPA-T — was ineffective in preventing thrombus formation in the FeCl₃, carotid artery injury model, consistent with the short half-life of uPA-T (Figure 6A). In contrast, using a bolus of uPA-T, followed by a 30-minute infusion of 5 mg/kg uPA-T, was as effective as 0.5 or 2.5 mg/kg PLT/uPA-T in preventing nascent thrombi from forming (Figure 6A). At a bolus infusion dose of 5 mg/kg uPA-T, an increase in rebleeding was observed in the tail-clipping studies, while no increase was seen with lower mg/kg uPA-T doses or with any tested dose of PLT/uPA-T (Figure 6B and Supplemental Figure 5).

We sought to examine the biology of PLT/uPA-T in the presence of human platelets in vivo. To do so, we studied the effects of PLT/uPA-T, uPA-T, and uPA alone in NSG mice infused with human platelets to a target level of 20% of total circulating platelets. At doses of uPA or uPA-T that prevented nascent clots from forming in the FeCl₃ model (Figure 6C), loss of hemostatic integrity was seen in the preexisting tail-clipping model (Figure 6D and Supplemental Figure 5). In contrast, at an effective dose of PLT/uPA-T (Figure 6C), little loss of hemostatic integrity was seen (Figure 6D). Moreover, unlike uPA and uPA-T, thromboprophylaxis with PLT/uPA-T was dependent on the presence of human platelets (Figure 6C). Thus, PLT/uPA-T was delivered to the site of injury by the human platelets. Without the presence of human platelets, PLT/uPA-T lost its effectiveness as a thromboprophylactic agent.

Models of nascent versus preexisting thrombi: cremaster arteriole laser injuries. Our tentative conclusion that PLT/uPA-T effectively lysed nascent, but not preexisting, clots could have resulted from our use of two distinct injury models to study nascent ver-

Discussion
PLT/uPA-T provides a unique combination of features that target a potent fibrinolytic prodrug to nascent clots, while exerting limited thrombolysis of even recently established clots. First, binding to circulating platelets prolongs the prodrug’s lifespan and facilitates its delivery to nascent clots due to natural platelet tropism. Second, platelet carryage inhibits the penetration of existing clots by soluble proenzyme uPA-T, thereby attenuating hemorrhage and probably other adverse effects in surrounding tissues. Third, uPA-T is a prodrug that is not subject to rapid inactivation and clearance by PAI-1. Fourth, PLT/uPA-T is activated by thrombin and not by the other serine proteases tested, including plasmin (8). Thrombin is preferentially expressed on the shell of nascent thrombi, where platelet turnover is occurring, whereas in preexisting clots, any residual thrombin is sequestered within the core, where it is less accessible to platelets (18). Drugs used in previous attempts to target uPA to platelets have lacked the thrombin activation mechanism, had short circulating half-lives, and failed to avoid systemic fibrinolysis (19).
PLT/uPA-T binds to both quiescent and activated human (and baboon) platelets in vitro and in vivo and neither induces nor inhibits platelet activation, thereby maintaining normal hemostatic pathways that drive platelets into clots. When injected into hαIIb+ mice that expressed hαIIb/mβ3 on their platelets (15), the half-life of PLT/uPA-T was approximately 2 hours (Figure 5A), which is approximately 100-fold longer than that of nontargeted uPA (20). This combination of high affinity for platelets and a prolonged half-life of PLT/uPA-T translated into an approximately 30-fold greater inhibition of clot growth than was seen with uPA-T alone using a bolus infusion approach (Figure 7), and an even greater difference if only a bolus was given (Figure 6). This difference was observed in spite of PLT/uPA-T being activated 2 times less efficiently by thrombin than was seen with uPA-T (Supplemental Figure 2). To circumvent the shorter half-lives of uPA and uPA-T, in vivo comparative studies were performed using a bolus infusion format. This intervention paradigm established that the increased thrombolytic activity of PLT/uPA-T was not solely due to its longer half-life, but was driven by platelet delivery to the clot.

Importantly, PLT/uPA-T, but not uPA or uPA-T, selectively lysed nascent versus preexisting clots when comparing both carotid arterial thrombosis with tail-clip rebleeding and a laser injury to cremaster arterioles before and after drug delivery. In both formats, the efficacy of PLT/uPA-T depended on the presence of human platelets for binding and delivery. The common injury model affirms that the selective agnosia of PLT/uPA-T for preformed clots is not the result of differences in sensitivity between models (e.g., carotid artery vs. tail-clip models), but can be seen when using a single model for the nascent and preexisting clots (e.g., before or after injuries in the cremaster arteriole laser injury model).

The importance of platelet targeting by the PLT/uPA-T is supported by our NSG mouse studies (Figures 6 and 7) showing that the fibrinolytic effects of PLT/uPA-T were only seen if the animals had been transfused with human platelets. This contrasted with uPA and uPA-T, whose fibrinolytic effects were seen with or without infused human platelets. Moreover, PLT/uPA-T lysed nascent clots as effectively as did the 30-fold-higher doses of uPA or uPA-T, even when less than 20% of the platelets were of human origin. These results are reminiscent of previous studies showing that thrombosis is prevented in WT mice when their platelet composition contains as little as 5% transfused QPD platelets (11) and affirm the potency of platelets as carriers of thrombolytic agents, and probably other cargos as well, to nascent clots.

In designing PLT/uPA-T as the target for the scFv moiety, we chose αIIbβ3, which is the most prevalent receptor on the surface of platelets, with up to 80,000 copies per platelet after activation (13). We selected an Ab template for the scFv part of the fusion that did not inhibit platelet aggregation (Figure 3C) and did not distinguish nonactivated from activated αIIbβ3. This enabled us to target all platelets, extend the drug’s half-life, and not perturb the normal targeting of platelets to sites where thrombi were forming. A previously reported chimeric construct of CD39 and also uPA with an αIIbβ3 scFv chimera (21, 22) bound only to activated αIIbβ3. The circulating half-life of this scFv/CD39 chimera
was not reported, but may have been very short, as it would have few, if any, receptors in the circulation, and its uPA portion would not be protected from proteolysis. On the other hand, the scFv/CD39, and perhaps the scFv/uPA, had a longer than 2-minute half-life on incorporated platelets within the thrombi, which presumably expressed activated surface αIIbβ3. This helps to explain the observed lack of an effect from the scFv chimeras when given as a bolus 3 minutes before a tail-clip injury, a setting without activated platelets to which these drugs can attach and prolong their half-lives. Presumably, in this setting, the drugs are cleared rapidly, and the tail-clip assay is unaffected. In contrast, when these drugs are given 3 minutes after the initiation of an FeCl3 carotid arterial injury, activated platelets are likely to have attached to the site of injury, bind the scFv chimeras, and initiate lysis (21). Therefore, we believe that these chimeras need to be tested using a bolus infusion format to eliminate these pharmacokinetic concerns and to better simulate the clinical usage of these chimeric drugs. These concerns also underscore the notion that the biology and clinical utility of platelet-directed drugs may be significantly influenced by the platelet receptor targeted, that this binding requires that receptor to be in a specific state of activation, and that the activated drug component of the chimera is subject to inactivation in the circulation.

We envision PLT/uPA-T being especially useful in settings such as after major pulmonary embolism, stroke, or trauma or following extensive surgery in which the risks of thrombosis are high, as is the possibility of hemorrhage due to breakdown of preexisting clots. Currently, thromboprophylaxis is routinely delayed for hours to days in these common situations because of the real concern for bleeding. Whether use of PLT/uPA-T, which exhibits a lead time as short as 10 minutes to seal and protect clots in mouse models, will prove applicable to human hemostasis will, of course, require additional studies. Studies will also be needed to determine whether this strategy will be useful in systemic prothrombotic states, including heparin-induced thrombocytopenia (Figure 3 and Supplemental Figure 4), in which the intent is to prevent disease progression by lysing nascent thrombi and preventing the onset of major vessel occlusion.

In summary, we have designed what we believe to be a novel PLT/uPA-T prodrug that selectively lyses nascent thrombi with relative sparing of preexisting clots. This new agent combines several important features: (a) the prodrug requires thrombin...
to be activated, which should prevent inactivation by PAI-1 in the circulation and limit activity to the site of actively growing thrombi; (b) the drug binds tightly to the surface of nonactivated platelets and has a half-life of several hours in the circulation; and (c) PLT/uPA-T proteolytic activity can be blocked using TEA in the event of bleeding. In several murine hemostasis/thrombosis models, PLT/uPA-T inhibited occlusive thrombi from forming after injury, while sparing preexisting thrombi. The agent is suitable for the study of more clinically relevant thrombosis models in baboons. Further studies should provide insight into the role of platelets in clot remodeling and help to develop unique platelet-targeting strategies for different clinical needs.

Methods

Murine lines studied

The hullB+ mice used in these studies were transgenic for human integrin αIIb (Tg(ITGA2B)). These hullB+ mice were backcrossed onto a C57BL/6 background more than 10 times, had platelets that expressed hullB levels at 1% to 20% of levels seen on human platelets (15), and were studied concurrently with their WT sibling littermates. These mice were genotyped by PCR analysis of tail genomic DNA using previously described primer pairs and reaction conditions. NOD/SCID/IL-2Rγ-deficient (NSG) mice (23) were produced in pathogen-free animal facilities at the CHOP using breeders obtained from The Jackson Laboratory. Six- to twelve-week-old NSG male mice were studied.

Anti-αIIbβ3 mAbs, generation of scFv chains, and final chimeric produgs

Various antiplatelet mAbs were analyzed by flow cytometry to characterize their binding specificity to human and WT and hullB+ mouse platelets (24). The mAb 312.8 was used to produce a platelet-specific scFv. Construction of the scFv and chimeric prodrug was performed following previously described techniques with modifications (Figure 1A and refs. 25, 26). Total RNA was isolated from 312.8 mAb hybridoma cells and reverse transcribed with RNasey (QIAGEN) using SMART technology (Clontech) with primers designed to isolate DNA encoding the variable heavy (VH) and variable light (VL) chain domains from mouse hybridoma cells (26). The VH and VL frag-
Figure 6. Prodrug efficacy versus nascent thrombi induced by FeCl₃-sclerosing versus preexisting thrombi induced by tail-clip injury. (A–D) Schematics of the study and results. Results and schematics shown in A and B involve hIIB⁺ mice. Prodrugs were given as a 2-minute bolus, followed by a 30-minute infusion dose at the indicated mg/kg dose, except for panel B, which refers to a bolus only. Data represent the mean ± 1 SEM and are shown by n values. ANOVA multiparametric analysis was performed, and P values are relative to the PBS control. (A) AUC of blood flow in the FeCl₃ injury model while receiving the indicated prodrug. AUC for blood flow is shown because, while all of the mice exposed to PBS or bolus uPA-T had total occlusions, none of the other mice developed total occlusions, but some developed partial occlusions that were notable by measuring the AUC. In B, tail-clip blood loss that occurred after the prodrug’s infusion was compared with blood loss prior to prodrug infusion. The time to stop bleeding, determined visually during the pre-drug window, was 2.1 ± 0.4 minutes, similar to that seen by others in similar models (32). Dashed lines in A–D indicate equal blood loss before and after drug exposure. Data shown in C and D represent studies analogous to those in A and B, respectively, but were conducted in NSG mice either infused (+) or not infused (−) with human platelets. The uPA and uPA-T dose for both the bolus and infusion was 5 mg/kg and 0.5 mg/kg for PLT/uPA-T. Data shown represent the mean ± 1 SEM. ANOVA multiparametric analysis was performed, and P values are relative to the PBS control.

Murine and human blood samples, platelet preparation, platelet aggregation, and flow cytometric studies

Human blood was collected in 0.129 M sodium citrate (10:1, vol/vol). Murine whole blood was collected from the inferior vena cava under direct observation and collected into acid citrate dextrose (ACD) as previously described (18). Platelet-rich plasma (PRP) was separated after centrifugation (200 g, 10 minutes) at room temperature (RT). The platelets were then isolated from PRP, and prostaglandin E1 (Sigma-Aldrich) was added to a final concentration of 1 μM. Platelets were then pelleted by centrifugation (800 g, 10 minutes) at RT. The pellet was washed in calcium-free Tyrode’s buffer (134 mM NaCl, 3 mM KCl, 0.3 mM NaH₂PO₄, 2 mM MgCl₂, 5 mM HEPES, 5 mM glucose, 0.1% NaHCO₃, and 1 mM EDTA, pH 6.5), and resuspended in CATCH buffer (PBS and 1.5% bovine serum albumin, 1 mM adenosine, 2 mM theophylline, 0.38% sodium citrate, all from Sigma-Aldrich). Platelet counts were determined using a HemaVet counter (Triad Associates). Platelet aggregation studies with the mAb 312.8 were performed as previously described (27) using human PRP adjusted to 3 × 10⁹ platelets/μl with platelet-poor plasma (PPP). Samples of these platelets were either untreated or incubated for 5 minutes at 37°C with 20 μg/ml mAb. Platelet aggregation was induced by adding 10 μM ADP to the platelet preparations, and light transmission was measured over time in a Kowa AG-10E aggregometer under continuous stirring. Flow cytometry (using a BD FACScan) was used to measure the binding of 1 μg 312.8 mAb and uPA-T or PLT/uPA-T to resting or PMA-activated (50 μM) washed platelets (1 × 10⁶/μl). To detect platelet-bound uPA-T or PLT/uPA-T, anti-FLAG M2-FITC mAb (Sigma-Aldrich) and a phycoerythrin-labeled (PE-labeled) anti-human CD41 mAb (eBioscience) were incubated sequentially with the samples for 30 minutes each prior to analysis. To detect bound 312.8 mAb, a goat anti-mouse IgG-FITC Ab (eBioscience) was used. In some studies, binding was detected by directly labeling the 312.8 mAb and the fusion protein with Alexa Fluor 647 (Invitrogen) and incubating 1 μg labeled protein with platelets before analysis.

Binding specificity of PLT/uPA-T was analyzed by flow cytometry using human and murine WT and hIIB⁺ platelets. Binding was also assessed by radiolabeling the PLT/uPA-T with ¹²⁵I-Na (PerkinElmer) in iodination tubes (Thermo Scientific). After blocking with 5% PBS/BSA and washing with PBS/Tween-20, various concentrations of PLT/uPA-T (100 μl/well) were incubated with human αIβ3 or BSA coated wells for 1 hour at 37°C. Nonbound material was removed by washing with PBS/Tween-20, and residual radioactivity was measured on a γ-counter (PerkinElmer).

PLT/uPA-T thrombin activation and specificity of activation

Activation of PLT/uPA-T by thrombin was measured using bovine fibrinogen (Sigma-Aldrich) dissolved in PBS to a final concentration of 3 mg/ml. Clotting was induced by addition of 20 mM CaCl₂ and 0.2 units/ml thrombin (Sigma-Aldrich), and the resulting solution was immediately added to a 24-well cell culture plate (0.75 ml/well), where clots were allowed to mature for 30 minutes. uPA-T or PLT/uPA-T was activated by incubation with 20 nM bovine thrombin...
The kinetics of PLT/uPA-T and uPA-T activation by thrombin was studied over a 1.5-hour period using the uPA-specific chromogenic peptide substrate pyroGlu-Gly-Arg-pNA·HCl (Spectrozyme uPA; American Diagnostica Inc.). PLT/uPA-T or uPA-T (10 nM final concentration) was mixed with Spectrozyme uPA (1.67 mM final concentration) in the absence or presence of 1 nM bovine thrombin (Amersham, GE Healthcare Life Sciences). Thrombin, PLT/uPA-T, and uPA-T were each used alone as negative controls to ensure that they did not possess amidolytic activity toward the Spectrozyme uPA substrate. Cleavage of the chromogenic substrate by activated PLT/uPA-T or uPA-T was monitored by measuring the optical density at 405 nm on an ELISA plate reader every 15 seconds.

To study the sensitivity of the activation reaction to antithrombin III, thrombin was premixed with Antithrombin III (Sigma-Aldrich) (thrombin/antithrombin ratio of 1:2) and then added to the mixture of PLT/uPA-T or uPA-T with Spectrozyme uPA substrate. The kinetics of activation of PLT/uPA-T or uPA-T was measured as above. To affirm thrombin specificity, PLT/uPA-T–generated amidolytic activity was tested after a 1-hour incubation with 5 nM thrombin at 37°C. These studies were repeated with human elastase, chymase, tryptase, plasmin, heat-inactivated thrombin, activated protein C, or kallikrein (all from Sigma-Aldrich). Thrombin was inactivated by heating at 100°C for 30 minutes to distinguish between the requirement for its catalytic and noncatalytic activi-
ties. The resulting amidolytic activity was assayed in activity buffer (50 mM Tris, pH 7.5, 30 KIU/ml aprotinin, and 33 U/ml hirudin) as described previously (28).

Prodrug half-life and activity in huHb\(^+\) mice

uPA-T (5 mg/kg), PLT/uPA-T (0.25 mg/kg), or PBS was labeled with Alexa Fluor 647 (Invitrogen, Thermo Fisher Scientific) and infused i.v. into huHb\(^+\) mice. The prodrug doses were chosen on the basis of their efficaciousness in the microfluidic system (Figure 5) and/or in vivo (Figures 6 and 7). Retroorbital blood was collected into a minipipetation blood collection tube (RAM Scientific) prior to infusions and at time points extending up to 72 hours after infusion. Platelet-bound PLT/uPA-T and uPA-T were analyzed by flow cytometry. Platelet counts were measured at time points after a single infusion for up to 24 hours using a HemaVet counter (Triad Associates). Fibrinogen and D-dimer levels were measured in mice before and after prodrug infusions using the Mouse Fibrinogen ELISA kit (Molecular Innovations) and a Mouse FDP ELISA kit (Novatine Biosciences), respectively.

Microfluidic studies of thrombolysis

Human PRP was isolated from whole blood collected in 3.8% sodium citrate (1:10, v/v), uPA-T or PLT/uPA-T (10 µg/ml each) and calcine AM (2 µM) (Invitrogen) were added for 30 minutes at RT. The PRP was then passed through a column packed with 20 ml Sepharose CL-2B (GE Healthcare), then prewashed and equilibrated with calcium-free Tyrode’s buffer. Analysis of platelet-bound drug was performed by flow cytometry. These gel-filtered platelets were added back to the PRP-depleted blood to reconstitute “whole blood.” The blood was then activated by either adding recombinant FVIIa (80 nM, ref. 16) or inducing an HIT-like prothrombotic state by adding 5 mM CaCl\(_2\). The samples were then flowed through a BioFlux microchannel (Fluxion Biosciences) coated with 20 µg/ml human vWF (American Diagnostica) for 20 minutes at 20 dyn/cm\(^2\). Image and video acquisition was obtained with an Observer Z.1 inverted microscope (Zeiss). The surface area covered by calcine-labeled platelets and Alexa Fluor 647–labeled fibrinogen/fibrin was analyzed using BioFlux Montage software (Fluxion Biosciences).

Murine hemostasis models to demonstrate PLT/uPA-T thromboprophylaxis

FeCl\(_3\), carotid artery and tail-clipping injury murine models. Two models of hemostasis/thrombosis were used to evaluate whether the PLT/uPA-T targeted nascent thrombi, while sparing preexisting ones. In the first model, nascent carotid arterial thrombi were induced in huHb\(^+\) mice using FeCl\(_3\), (11), and preexisting thrombi were studied using a tail-clipping injury model (29, 30). The models were modified to also study NSG, rather than huHb\(^+\), mice infused with human platelets. In both iterations, mice were first anesthetized by i.p. injection of pentobarbital (80 mg/kg nembutal; Ovation Pharmaceuticals). NSG mice were then infused retro-orbitally with washed human platelets so that approximately 20% of the circulating platelets were of human origin (determined by flow cytometry using a combination of PE-conjugated rat anti-mouse CD41 and FITC-conjugated mouse anti-human CD41a). For the carotid artery injury study, 12.5%–15% FeCl\(_3\), was applied for 2 minutes (11). An i.v. bolus of the test prodrug was administered 2–2.5 minutes before injury as a bolus alone or with a subsequent continuous infusion for 30 minutes. Total flow and time to the first complete occlusion of more than 7 minutes were recorded. Preexisting tail-injury thrombi were produced by amputating an 8-mm terminal tail segment, which was then placed in a collection tube containing sterile water at 37°C for 10 minutes. The tail was then placed in a new collection tube, and a bolus of LMW uPA or its derivative uPA-T or PLT/uPA-T was administered i.v., followed by continuous infusion for 30 minutes. The amount of hemoglobin in the water was measured with a spectrophotometer as described previously (31, 32). Briefly, the hemolyzed whole blood and water mixture was centrifuged at 15,000 g for 5 minutes. Aliquots (10 µl) of clarified, stroma-free supernatant were diluted 10-fold in a 96-well microplate (Corning), and light absorbance was measured at 576 nm with a SpectraMax 190 Microplate Reader (Molecular Devices). Blood loss during the 30-minute time window was normalized for the blood loss during the earlier 10-minute observation period to account for differences in the extent of initial injuries and severity of initial bleeding.

Early and late cremaster arteriole laser injury murine model. To confirm the potential of PLT/uPA-T to lyse nascent thrombi while sparing preexisting ones, we used the cremaster laser-induced thrombosis system (33) as a second model. NSG male mice were studied after being anesthetized using i.p. injected sodium pentobarbital (60 mg/kg). The mice were maintained under anesthesia with the same anesthetic delivered via a catheterized jugular vein at 5 mg/ml throughout the experiment. Human platelets were resuspended in PBS and infused into the jugular vein, followed by Alexa Fluor 647– or 488–conjugated rat anti-mouse CD41 Fab\(_2\) fragments (BD Biosciences) to label endogenous mouse platelets and Alexa Fluor 647–labeled anti-fibrin 9D8 Ab (34). Laser injuries were induced in cremaster arterioles before and after PBS or uPA or uPA-T or PLT/uPA-T by i.v. bolus plus continuous infusion. Wide-field images of thrombi were captured using SlideBook 6.0 (Intelligent Imaging Innovations), and intensity of signal over the thrombus was used to measure incorporated platelets and fibrin (33). Locations of predrug injuries were marked in the software to revisit and recapture after the bolus and continuous infusion of drug or PBS. Analysis of images was performed using SlideBook 6.0 (35). Data were collected over a 3-minute period for each injury. Up to 8 injuries were made in each mouse.

Statistics

Data in Figures 4 and 5 were compared with WT controls by Student’s \( t \) test using Prism 5.0 (GraphPad Software). Data in Figures 6 and 7 were analyzed using ANOVA with post-test comparisons against controls or within groups by Dunnett’s correction where appropriate. Multiplicity-adjusted \( P \) values are reported. For all analyses, a \( P \) value of less than 0.05 was considered significant.

Study approval

Human blood samples were obtained from healthy volunteers, who provided written informed consent. Studies were approved by the IRB of the CHOP. All animal experiments were approved by the IACUC of the CHOP, and all investigators adhered to NIH guidelines for the care and use of laboratory animals.
Author contributions

REF and SZ developed the construct, expressed and purified the proteins, conducted the initial in vitro studies, and contributed to the intellectual development of the project and the preparation of the manuscript. HSA completed the in vitro studies. HSA and VH carried out the in vivo studies and assisted with the preparation of the manuscript. MAK and YW assisted with the platelet-related studies. MPL performed the statistical analysis of the results. DLS helped with the design and data interpretation related to the scFv. DWB and RHA contributed the Abs screened and to the design and interpretation of related studies. DDM assisted with the baboon studies and their interpretation. VS assisted with developing the scFv construct and with the pharmacokinetic studies. DBC, VRM, and MP designed the project, oversaw its performance, provided data interpretation, and assisted with manuscript preparation.

Acknowledgments

This work was supported by NIH grants PO1 HL40387 (to D.B. Cines, V.R. Muzykantov, M. Poncz, and S. Zaitsev), RO1 HL013629 (to D.W. Bougie and R.H. Aster), and T32 HL07971 (to R.E. Fuentes).

Address correspondence to: Mortimer Poncz, The Children’s Hospital of Philadelphia, 3615 Civic Center Blvd., ARC, Rm. 317, Philadelphia, Pennsylvania 19104, USA. Phone: 215.590.4374; E-mail: poncz@email.chop.edu.


